TL;DR
Tirzepatide, the active ingredient in Mounjaro and Zepbound, produced 15.0 to 20.9% body weight loss across doses in the SURMOUNT-1 trial over 72 weeks. It is the first dual GIP/GLP-1 receptor agonist approved for weight management. Below you will find dose-by-dose breakdowns, week-by-week timelines, and clinical trial summaries.
Tirzepatide is the most effective weight loss medication studied in large clinical trials to date. If you have seen it referred to by multiple names, here is the short version: tirzepatide is the drug. Mounjaro is the brand name for type 2 diabetes.
Zepbound is the brand name for weight management. The molecule is identical across all three.
Understanding the before-and-after data for tirzepatide means looking at the SURMOUNT trial program, which tested the drug across multiple populations and dosage levels. The results are consistently strong, and they represent the clearest picture of what you can expect from treatment.
What Weight Loss Results Does Tirzepatide Produce?
In the SURMOUNT-1 trial, tirzepatide at the 15 mg dose produced an average body weight loss of 20.9% over 72 weeks. That makes it the most effective injectable weight loss medication tested in a phase 3 trial, according to data published in the New England Journal of Medicine. The trial enrolled 2,539 participants.
The results were dose-dependent, meaning higher doses produced greater weight loss. Even the lowest therapeutic dose of 5 mg produced results comparable to or exceeding other GLP-1 medications at their maximum doses.
| Dose | Avg Body Weight Loss | Avg Pounds Lost (240 lb start) | % Losing 10%+ | % Losing 20%+ |
|---|---|---|---|---|
| 5 mg | 15.0% | ~36 lbs | 69% | 32% |
| 10 mg | 19.5% | ~47 lbs | 80% | 52% |
| 15 mg | 20.9% | ~50 lbs | 84% | 57% |
| Placebo | 3.1% | ~7 lbs | 15% | 3% |
In the 15 mg group, 57% of participants lost 20% or more of their body weight. That level of weight loss was essentially unheard of with previous medications and approaches the results seen with bariatric surgery.
How Does Tirzepatide Work Differently from Semaglutide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist, which means it activates two incretin hormone receptors simultaneously. Semaglutide-based drugs like Wegovy and Ozempic only target the GLP-1 receptor. This dual mechanism is the primary reason tirzepatide produces greater average weight loss in clinical trials.
Check out our see real Zepbound results for detailed data.
GIP (glucose-dependent insulinotropic polypeptide) was historically considered a less important metabolic hormone. Research on tirzepatide changed that understanding. The GIP receptor activation appears to enhance the fat-burning effects and may contribute to better preservation of lean body mass compared to GLP-1-only medications.
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Receptor targets | GIP + GLP-1 (dual) | GLP-1 only |
| Max approved dose (weight loss) | 15 mg weekly | 2.4 mg weekly |
| Avg weight loss (highest dose) | 20.9% | 14.9% |
| % losing 20%+ body weight | 57% | ~33% |
| GI side effect profile | Slightly milder per unit of weight loss | Higher rates of nausea and vomiting |
| Administration | Once weekly injection | Once weekly injection |
The practical takeaway is that tirzepatide tends to produce more weight loss with a comparable or slightly milder side effect profile. However, both medications are highly effective, and some patients respond better to one than the other.
What Is the Week-by-Week Tirzepatide Timeline?
Weight loss on tirzepatide follows a gradual acceleration pattern, with the most rapid losses occurring between weeks 12 and 40. The medication starts at 2.5 mg and is titrated upward every four weeks. Noticeable appetite changes typically begin within the first two weeks of treatment.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →The titration schedule is designed to minimize side effects. Rushing to higher doses increases gastrointestinal symptoms without improving long-term outcomes. Patience during the escalation phase pays off.
| Timeframe | Typical Dose | What to Expect | Estimated Cumulative Loss |
|---|---|---|---|
| Weeks 1 to 4 | 2.5 mg | Appetite begins to decrease. Some GI adjustment. Mild nausea common. | 2 to 4% |
| Weeks 5 to 8 | 5 mg | Stronger appetite suppression. Portions shrink naturally. Energy stabilizes. | 4 to 7% |
| Weeks 9 to 16 | 7.5 to 10 mg | Rapid weight loss phase begins. Visible body changes. Lab values improve. | 8 to 13% |
| Weeks 17 to 32 | 10 to 15 mg | Continued steady loss. Clothing sizes drop. Metabolic markers normalize. | 14 to 19% |
| Weeks 33 to 72 | 15 mg | Loss slows as you approach plateau. Focus on body composition and maintenance. | 18 to 22% |
Patients with type 2 diabetes typically follow the same titration but may see slightly slower weight loss. The SURMOUNT-2 trial showed 14.7% average loss in this population, which is still highly significant.
What Are Tirzepatide Side Effects?
The side effect profile for tirzepatide is dominated by gastrointestinal symptoms, particularly during dose escalation. In SURMOUNT-1, nausea occurred in 24% of participants at the 15 mg dose versus 6% on placebo. Most side effects were rated mild to moderate and resolved as the body adjusted to each new dose level.
Compared to semaglutide, tirzepatide appears to cause fewer GI side effects relative to the amount of weight lost. The SURPASS-2 trial, which compared tirzepatide directly to semaglutide 1 mg for type 2 diabetes, showed comparable tolerability with superior weight loss.
| Side Effect | Tirzepatide 15 mg | Placebo | Typical Resolution |
|---|---|---|---|
| Nausea | 24% | 6% | 2 to 4 weeks per dose step |
| Diarrhea | 17% | 9% | 1 to 3 weeks |
| Constipation | 11% | 5% | Variable, often ongoing |
| Vomiting | 9% | 2% | 1 to 2 weeks per dose step |
| Injection site reactions | 5% | 2% | Minutes to hours |
| Decreased appetite | 9% | 1% | Ongoing (therapeutic) |
Serious adverse events were rare. The FDA label includes warnings about pancreatitis, gallbladder disease, and thyroid C-cell tumors (based on rodent data). Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2.
What Do the SURMOUNT Trials Tell Us?
The SURMOUNT program includes four major trials that collectively enrolled over 5,000 participants, making it one of the largest clinical trial programs for any weight management medication. SURMOUNT-1 established the efficacy baseline, and subsequent trials explored performance in specific populations and conditions.
Each trial answered a distinct clinical question about tirzepatide's role in weight management.
| Trial | Population | n | Duration | Key Result (15 mg) |
|---|---|---|---|---|
| SURMOUNT-1 | Obesity, no diabetes | 2,539 | 72 weeks | 20.9% body weight loss |
| SURMOUNT-2 | Obesity + type 2 diabetes | 938 | 72 weeks | 14.7% body weight loss |
| SURMOUNT-3 | Intensive lifestyle + medication | 579 | 72 weeks | 26.6% body weight loss |
| SURMOUNT-4 | Continuation vs withdrawal | 670 | 88 weeks | ~14% regain after switching to placebo |
SURMOUNT-3 deserves special attention. When tirzepatide was combined with an intensive lifestyle program that included a 12-week low-calorie diet lead-in, participants lost 26.6% of body weight. That figure is in the range of outcomes seen with bariatric surgery, achieved entirely through medication and behavioral intervention.
SURMOUNT-4 confirmed that tirzepatide, like other GLP-1 medications, works best as ongoing therapy. Stopping the medication led to substantial weight regain, reinforcing the clinical consensus that obesity is a chronic condition requiring sustained treatment.
Is Compounded Tirzepatide an Option?
Compounded tirzepatide is available from licensed compounding pharmacies at a fraction of the brand-name cost, typically $249 to $399 per month compared to $1,000+ for Mounjaro or Zepbound without insurance. The active ingredient is the same, and reputable compounding pharmacies follow FDA-regulated quality standards.
The FDA has allowed compounding of tirzepatide during periods of drug shortage. FormBlends works exclusively with licensed pharmacies that undergo third-party purity and potency testing. Patients receive the same dosing, titration schedule, and physician oversight as those on brand-name products.
If cost is a barrier, compare compounded tirzepatide pricing here.
How to Maximize Your Tirzepatide Results
The SURMOUNT-3 data makes a compelling case for combining medication with lifestyle optimization. Patients who paired tirzepatide with intensive behavioral therapy lost 26.6% of body weight, roughly 6 percentage points more than medication with standard lifestyle counseling alone.
Protein intake is the single most important dietary factor. Aim for 1.0 to 1.2 grams of protein per kilogram of body weight daily. This helps preserve lean muscle mass, which is critical because approximately 25 to 40% of weight lost on GLP-1 medications can come from lean tissue without adequate countermeasures.
Resistance training 2 to 3 times per week directly addresses muscle preservation. Combined with adequate protein, strength training can significantly shift the ratio of fat loss to lean mass loss in your favor. Even basic bodyweight exercises make a measurable difference.
Use the FormBlends weight loss timeline calculator to model your projected results based on starting weight and target dose.
Frequently Asked Questions
What is the difference between tirzepatide and Mounjaro?
Tirzepatide is the generic drug name. Mounjaro and Zepbound are brand names for the same medication made by Eli Lilly. Mounjaro is approved for type 2 diabetes, while Zepbound is approved for weight management.
The active ingredient is identical.
How much weight can you lose on tirzepatide?
Clinical trials show average weight loss of 15.0% at the 5 mg dose, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks. Individual results vary based on starting weight, dose, diet, and physical activity.
How long does it take to see results on tirzepatide?
Most patients notice reduced appetite within the first 1 to 2 weeks. Visible weight loss typically becomes apparent by weeks 4 to 8. The most significant results occur between months 3 and 9 of treatment.
Is tirzepatide better than semaglutide?
Tirzepatide has produced greater average weight loss in clinical trials compared to semaglutide: 20.9% vs 14.9% at their respective highest doses. However, individual responses vary, and the best medication depends on your specific health profile, tolerance, and insurance coverage.
What are the side effects of tirzepatide?
The most common side effects are gastrointestinal: nausea (24%), diarrhea (17%), and constipation (11%) at the 15 mg dose. These typically occur during dose escalation and improve over time. Serious side effects are rare.
Can you get compounded tirzepatide?
Compounded tirzepatide is available from licensed compounding pharmacies. It contains the same active ingredient as Mounjaro and Zepbound at a significantly lower price point. FormBlends offers compounded tirzepatide starting at $249 per month with physician oversight.
Does tirzepatide work for people with type 2 diabetes?
Yes. The SURMOUNT-2 trial specifically studied tirzepatide in adults with obesity and type 2 diabetes. Participants lost an average of 14.7% of body weight at the 15 mg dose over 72 weeks, along with significant improvements in blood sugar control.
What happens if you stop taking tirzepatide?
Weight regain is common after discontinuation. The SURMOUNT-4 trial showed patients who switched from tirzepatide to placebo regained approximately 14% of body weight over 52 weeks. Most clinicians recommend ongoing treatment for sustained results.